GoodRx Holdings Inc (GDRX)
7.495
-0.56
(-7.01%)
USD |
NASDAQ |
May 17, 16:00
7.495
0.00 (0.00%)
After-Hours: 16:06
GoodRx Holdings Research and Development Expense (Quarterly): 31.02M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 31.02M |
| December 31, 2023 | 32.03M |
| September 30, 2023 | 39.61M |
| June 30, 2023 | 31.28M |
| March 31, 2023 | 32.91M |
| December 31, 2022 | 36.77M |
| September 30, 2022 | 35.92M |
| June 30, 2022 | 35.40M |
| March 31, 2022 | 35.04M |
| December 31, 2021 | 35.06M |
| Date | Value |
|---|---|
| September 30, 2021 | 35.07M |
| June 30, 2021 | 29.57M |
| March 31, 2021 | 26.16M |
| December 31, 2020 | 23.68M |
| September 30, 2020 | 15.85M |
| June 30, 2020 | 11.96M |
| March 31, 2020 | 10.32M |
| December 31, 2019 | 9.82M |
| September 30, 2019 | 7.844M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.844M
Minimum
Sep 2019
39.61M
Maximum
Sep 2023
27.12M
Average
31.28M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
| Sharecare Inc | 14.54M |
| American Well Corp | 26.68M |
| MultiPlan Corp | -- |
| Privia Health Group Inc | -- |
| GeneDx Holdings Corp | 11.57M |